Newsfeeds Archive - Spark Newswire

2 minute read

Uncategorized

Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment

June 18, 10:19 AM

AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a treatment forpatients suffering from specific type of endometrial cancer.

AZN

2 minute read

AstraZeneca’s Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial

By Vandana Singh

June 18, 9:22 AM

AstraZeneca announced that the CAPItello-290 Phase 3 trial for Truqap (capivasertib) combined with paclitaxel in advanced or metastatic triple-negative breast cancer did not meet primary endpoints for overall survival.

AZN

2 minute read

What’s Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?

By Vandana Singh

June 17, 11:47 AM

Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for relapsed/refractory B-cell malignancies

AZN

2 minute read

FDA Approves AstraZeneca Treatment For Advanced Endometrial Cancer

By Shivani Kumaresan

June 17, 6:38 AM

AstraZeneca's breakthrough drug, Imfinzi, combined with chemotherapy, has been officially approved by the FDA to treat advanced forms of endometrial cancer with mismatch repair deficiency. This critical approval is based on Phase III trial results showing a 58% reduction in disease progression, promising improved outcomes for those battling this severe cancer.

AZN

2 minute read

AstraZeneca Says Calquence/Chemo Combo Data Shows Additional 16.8 Months Without Disease Progression In Patients With Certain Type Of Blood Cancer

By Vandana Singh

June 17, 5:32 AM

AstraZeneca shares data from the ECHO Phase 3 trial on Calquence plus bendamustine and rituximab in untreated mantle cell lymphoma patients over 65.

AZN

1 minute read

Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca’s Drug

By Vandana Singh

May 29, 12:51 PM

The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare diseases.

AMGN

2 minute read

Why Is AstraZeneca Stock Trading Lower On Tuesday?

By Vandana Singh

May 28, 2:32 PM

AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance.

AZN

2 minute read

AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report

By Benzinga Neuro

May 27, 7:12 AM

Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers.

AZN

2 minute read

Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies

By Vandana Singh

May 23, 2:00 PM

U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medical equipment companies accused of supporting terrorism in Iraq.

AZN

1 minute read

Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity

By Vandana Singh

May 23, 12:53 PM

Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now focus on its PRMT5 program and plans to update on TNG908 and TNG462 later this year.

AZN